|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1998-3-13
|
|
pubmed:abstractText |
Abciximab (ReoPro; Eli Lilly and Co, Indianapolis, IN) is a monoclonal antibody that binds to the platelet glycoprotein IIb/IIIa receptor and produces powerful inhibition of platelet function. Clinical trials of abciximab in patients undergoing coronary angioplasty have demonstrated a reduction in thrombotic complications and have encouraged the widespread use of this agent. We have observed a substantial incidence of excessive bleeding among patients who receive abciximab and subsequently require emergency cardiac operations.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0003-4975
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
65
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
465-9
|
|
pubmed:dateRevised |
2005-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:9485247-Adult,
pubmed-meshheading:9485247-Aged,
pubmed-meshheading:9485247-Antibodies, Monoclonal,
pubmed-meshheading:9485247-Blood Loss, Surgical,
pubmed-meshheading:9485247-Cardiac Surgical Procedures,
pubmed-meshheading:9485247-Emergency Treatment,
pubmed-meshheading:9485247-Female,
pubmed-meshheading:9485247-Humans,
pubmed-meshheading:9485247-Immunoglobulin Fab Fragments,
pubmed-meshheading:9485247-Male,
pubmed-meshheading:9485247-Middle Aged,
pubmed-meshheading:9485247-Platelet Aggregation Inhibitors,
pubmed-meshheading:9485247-Postoperative Hemorrhage
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Abciximab and excessive bleeding in patients undergoing emergency cardiac operations.
|
|
pubmed:affiliation |
Division of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pennsylvania 15213, USA. gam@med.pitt.edu
|
|
pubmed:publicationType |
Journal Article
|
